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BACKGROUND: Health-related quality of life (HRQoL) was an exploratory endpoint in the PALETTE trial, a global, double-blind,
randomized, phase 3 trial of pazopanib 800 mg versus placebo as second-line or later treatment for patients with advanced soft tis-
sue sarcoma (N5369). In that trial, progression-free survival was significantly improved in the pazopanib arm (median, 4.6 vs 1.6
months; hazard ratio, 0.31; P<.001), and toxicity of pazopanib consisted mainly of fatigue, diarrhea, nausea, weight loss, and hyper-
tension. METHODS: HRQoL was assessed using the 30-item core European Organization for the Research and Treatment of Cancer
(EORTC) Quality-of-Life Questionnaire (EORTC QLQ-C30) at baseline and at weeks 4, 8, and 12 in patients who received treatment
on protocol. The primary HRQoL endpoint was the EORTC QLQ-C30 global health status scale. RESULTS: Compliance with HRQoL
assessments was good, ranging from 94% at baseline to 81% at week 12. Differences in scores on the EORTC QLQ-C30 global health
status subscale between the 2 treatment arms were not statistically significant and did not exceed the predetermined, minimal clini-
cally important difference of 10 points (P5.291; maximum difference, 3.8 points). Among the other subscales, the pazopanib arm
reported significantly worse symptom scores for diarrhea (P<.001) loss of appetite (P< .001), nausea/vomiting (P<.001), and fatigue
(P5.012). In general, HRQoL scores tended to decline over time in both arms. CONCLUSIONS: HRQoL did not improve with the
receipt of pazopanib. However, the observed improvement in progression-free survival without impairment of HRQoL was considered
a meaningful result. The toxicity profile of pazopanib was reflected in the patients’ self-reported symptoms but did not translate into
significantly worse overall global health status during treatment. Cancer 2015;121:2933-41. VC 2015 American Cancer Society.
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INTRODUCTION
Soft tissue sarcomas (STS) are a rare and heterogeneous collection of mesenchymal cancers. Patients with advanced STS
have a poor prognosis, with median overall survival (OS) of approximately 12 months from diagnosis of metastatic dis-
ease.1 Therefore, treatment strategies should aim at more active treatments while also limiting treatment-related morbid-
ity, controlling or alleviating symptoms, and retaining the performance of normal daily activities in as far as possible.
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Patients with advanced STS often report difficulties with
fatigue, pain, or respiratory symptoms, which can reduce
their health-related quality of life (HRQoL) or restrict
their independence.2,3 These difficulties are caused not
only by the disease itself but also by the treatment.
Because of the success of imatinib in producing a
dramatic improvement in disease control by targeting
KIT and platelet-derived growth factor (PDGF) in gas-
trointestinal stromal tumors,4 there has been a major
focus on identifying sarcoma subtypes with the appropri-
ate targets for novel molecular-targeted agents. This has
caused further fragmentation of treatment strategies in
this already limited patient population.5 STS growth is
characterized by accelerated angiogenesis6; therefore, in-
hibiting this process could form an effective treatment
strategy. Pazopanib (Votrient; GlaxoSmithKline Oncol-
ogy, Uxbridge, UK) is a selective, multitargeted receptor
tyrosine kinase inhibitor of vascular endothelial growth
factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3,
PDGFR-a, PDGFR-b, and KIT. The PALETTE study,
a global, double-blind, randomized, phase 3 trial that
compared the efficacy of pazopanib versus placebo for
the treatment of metastatic STS, investigated the
HRQoL of patients in addition to progression-free sur-
vival (PFS) and OS. It is the only published phase 3
study to date of patients after failure on standard therapy
for advanced STS.7
That study demonstrated that PFS was significantly
prolonged with pazopanib (median, 18 weeks) compared
with placebo (median, 6 weeks; hazard ratio, 0.31; 95%
confidence interval [CI], 0.24-0.40; P< .0001).8 The
reported adverse events were representative of those
expected for an angiogenesis inhibitor, with common on-
therapy grade 3 and 4 toxicities in the pazopanib arm
including fatigue (13%), hypertension (7%), anorexia
(6%), and diarrhea (5%). Clinically relevant cardiac side
effects were limited and manageable.
An exploratory objective of this study was to com-
pare HRQoL outcomes between the 2 treatment arms
using 2 psychometrically validated instruments that are
widely used in trials of cancer patients: the 30-item core
European Organization for the Research and Treatment
of Cancer (EORTC) Quality-of-Life Questionnaire
(EORTC QLQ-C30),9 and the EuroQol 5D instrument
(EQ-5D).10 The current article focuses on reporting
detailed HRQoL results from the EORTC QLQ-C30 in
line with the requirements established by the Consoli-
dated Standards of Reporting Trials Patient-Reported
Outcomes extension.11 EQ-5D data were used for cost-
effectiveness analyses reported elsewhere.12,13
MATERIALS AND METHODS
Patients
The PALETTE study (EORTC 62072, GlaxoSmithKline
VEG110727, and European Clinical Trials Database
[EudraCT] 2008-001307-33) enrolled patients who had
metastatic STS with documented, measurable progressive
disease (during the last 6 months before the start of study
drug or 12 months in patients who had received prior ad-
juvant treatment). Patients were aged 18 years, had a
World Health Organization (WHO) performance status
0 or 1, and had failed at least 1 anthracycline-containing
regimen. Full details of the eligibility criteria are reported
elsewhere.8 HRQoL assessments were described for
patients in the informed consent form. The study proto-
col was approved by the local ethics committees and regis-
tered at clinicaltrials.gov (NCT00753688).
Study Design
PALETTE was a randomized, double-blind, placebo-
controlled, phase 3 trial conducted by the EORTC Soft
Tissue and Bone Sarcoma Group across 72 sites world-
wide. The primary objective was to demonstrate superi-
ority in PFS (defined as the time from randomization to
either the first documentation of Response Evaluation
Criteria in Solid Tumors-defined disease progression
[according to an independent radiology review] or death
from of any cause) of pazopanib over placebo. Secondary
objectives included comparisons of OS, radiologically
confirmed objective responses, and safety profiles (results
reported previously7). An additional objective was to
compare HRQoL between treatment arms using the
EORTC QLQ-C30 instrument. Patients were random-
ized to the treatment arms in a 2:1 ratio to receive either
pazopanib 800 mg once daily or placebo using a central,
stratified, permuted block procedure. The stratification
factors were the number of previous lines of systemic
therapy received for advanced disease (0-1 vs 2 lines)
and WHO performance status (0 vs 1). Treatment con-
tinued until disease progression, unacceptable toxicity,
withdrawal of consent, or death. After discontinuation of
study treatment, further treatment was applied at the dis-
cretion of the patients and their physicians. The treat-
ment arm allocation remained blinded until the time of
final analysis or at the physician’s request upon disease
progression or medical emergency. No cross-over was
allowed.
Assessments
The EORTC QLQ-C30 (version 3.0) is a 30-item ques-
tionnaire that assesses HRQoL in cancer patients across 9
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multi-item scales: global health status (GHS), physical
functioning, role functioning, emotional functioning,
cognitive functioning, social functioning, fatigue, pain,
and nausea and vomiting. It also contains single-item
measures of dyspnea, insomnia, anorexia, constipation,
diarrhea, and financial impact).9 It has been translated
into many languages.14 Patients provide their answers on
a 4-point scale (from 1 [not at all] to 4 [very much]),
except for GHS, which has a 7-point scale (from 1 [very
poor] to 7 [excellent]). A linear transformation is used to
standardize the raw score, so that overall scores range from
0 to 100. For the EORTC QLQ-C30, a higher score on
GHS or on a functioning scale represents a better level of
quality of life and functioning, and a higher score on a
symptom scale represents a worse level of symptoms.15
Patients were asked to finish the questionnaires as com-
pletely as possible at the beginning of their hospital visit.
Administration of the HRQoL questionnaires fol-
lowed the clinical assessment schedule of the trial: the
EORTC QLQ-C30 was completed at baseline (from 2
weeks before randomization to the start of treatment) and
at weeks 4, 8, and 12 after starting treatment for patients
who received protocol-specified treatment, allowing a 1-
week window before and after the scheduled visit for ques-
tionnaire completion. If a patient discontinued protocol
treatment or was unblinded, then HRQoL was no longer
assessed. Guidelines for administering questionnaires
were provided, ensuring standardization of HRQoL data
by all personnel.16
Statistical Methods
The prespecified primary HRQoL outcome was GHS on
the EORTC QLQ-C30 to test the hypothesis that
patients who receive pazopanib would have improved
HRQoL compared with patients in the placebo arm. To
accommodate the repeated nature of the data, a linear
mixed-effects model was constructed with treatment,
time-effect and time-treatment interactions as fixed
effects, and a patient-specific random effect. This model
was applied to the data from all randomized patients, and
the most suitable covariance structure was determined on
the basis of Akaike Information Criterion.17 Score esti-
mates, standard errors, associated CIs, and subsequent
tests were obtained from the resulting model. The primary
test consisted of a general overall postbaseline test for no
differences between the 2 treatment arms at all postbase-
line time points using an overall F test statistic at a 5%
level of significance. Because missing data are a problem
in most HRQoL studies, sensitivity analyses were pre-
planned and performed investigating the informative
dropout by graphic evaluation and assessing the relation
between selected variables (sex and the stratification fac-
tors: performance status and number of previous lines)
and questionnaire compliance using logistic regression. In
these analyses, factors that were associated with the miss-
ing data process were included as additional covariates in
the mixed model. In addition, a linear regression model
was used to predict the value of these missing data and to
subsequently impute the data.18 The main analysis was
then repeated on this augmented data set. Further sensi-
tivity analyses included limiting patient selection to the
safety or per-protocol population, applying the primary
model to the other scales of the EORTC QLQ-C30, and
the use of summary statistics. For GHS, the difference
between the baseline assessment and subsequent assess-
ments was calculated 1) until the last available score, 2)
until the lowest available score, and 3) as the average of all
postbaseline scores. A final summary statistic was the per-
centage of patients reporting a change from baseline of
10-points at any time on the GHS scale. Differences of
at least 10 points (on a 0-100 scale) were chosen because
these correspond to the minimum clinically meaningful
change in the HRQoL parameter).19
In post-hoc exploratory analyses, factor analysis and
linear regression models were used to explore the correla-
tions between HRQoL scores. Linear regression also was
used to link relative dose intensities (ie, the amount of drug
administered proportional to the protocol drug schedule)
with HRQoL parameters. Prognostic factor analyses of
PFS and OS were performed using Kaplan-Meier techni-
ques and Cox proportional hazards regression. The explor-
atory tests were stratified for treatment allocation when
possible. All analyses were done using the statistical soft-
ware package SAS version 9.3 (SAS Institute, Cary, NC).
RESULTS
Patients
In total, 369 patients (123 in the placebo arm and 246 in
the pazopanib arm) were randomized in 16 months (Oc-
tober 2008 to February 2010) and represented the intent-
to-treat population. Baseline demographics and clinical
characteristics were well balanced between the 2 arms (Ta-
ble 1). Additional data are reported elsewhere.8
HRQoL Completion Rates and Baseline Scores
Completion rates for HRQoL questionnaires in the
intent-to-treat population are listed in Table 2. Compli-
ance with HRQoL assessment was good, and 94% of
patients completed the questionnaires at baseline. Com-
pliance rates slowly decreased over time, with the lowest
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rate reported at week 12 (78% and 81% for the placebo
and pazopanib arms, respectively). No statistically signifi-
cant differences in compliance rates between the 2 arms
were observed at any time point, but patients in the pla-
cebo arm tended to complete fewer questionnaires, largely
because of a higher progression rate. The median number
of completed questionnaires was 3 for the pazopanib
group and 2 for the placebo group. The mean and median
HRQoL scores at baseline for the EORTC QLQ-C30
scales were comparable between the 2 treatment arms.
Overall, compared with other studies, the compliance
rates in our trial were within all acceptable limits.20
GHS Modeling
The overall test for postbaseline differences between the
2 treatment arms resulting from the repeated measures
mixed effect with an unstructured covariance was not
significant (P5 .291). Differences in GHS between the
2 treatment arms assessed at each of the week-4, week-
8, and week-12 assessments were not statistically signifi-
cant and did not reach the predetermined minimal clin-
ically important difference of 10 points (Table 3). The
maximum observed difference occurred at week 4 and
was 23.8 points (95% CI, 29.0, 1.3), indicating a
lower score in the pazopanib arm, but it was not beyond
the 10-point threshold for clinical significance. Figure 1
illustrates the mean GHS scores estimated according to
the model and the corresponding 95% CIs. In both
arms, the mean GHS scores tended to decline over
time.
Missing Data Mechanism
An investigation into the reported reasons for missing
data revealed that the main documented reason was
administrative failure (either the patient or the staff for-
getting to complete the assessment), which accounted
for 63% of all reported reasons for missing data. Miss-
ingness was not related to selected clinical prognostic
variables.
Sensitivity Analyses
The mixed-effect model was replicated in the safety popu-
lation (overall test for difference, P5 282) and in the per-
protocol population (P5 .315). In addition, although no
variable was significantly linked to compliance, sex and
the stratification factors were added as extra fixed-effects
covariates (P5 .302). All of these models yielded very
similar results. Explicit regression imputation with
imputed values predicted from a regression model that
included certain variables (time, treatment group, sex,
age, WHO performance score, the number of previous
lines of systemic treatment for advanced disease) also con-
firmed that there were no significant differences (Support-
ing Table 1; see online supporting information). The
change in GHS scores from baseline between the 2 treat-
ment arms in terms of average or last reported scores were
not clinically significant. However, a difference in terms
of the minimum number and proportion of patients expe-
riencing a 10-point decrease was reported, both in favor
of the placebo arm (Table 4).
TABLE 2. Summary of QLQ-C30 Completion Rates
Compliance: No. of Forms Received/Expected (%)a
Treatment Arm Baseline Wk 4 Wk 8 Wk 12
Placebo arm 115/123 (93.5) 96/103 (93.2) 55/67 (82.1) 31/40 (77.5)
Pazopanib arm 232/246 (94.3) 194/220 (88.2) 148/179 (82.7) 126/155 (81.3)
a No statistically significant differences in compliance were observed between the 2 arms.
TABLE 1. Baseline Characteristics
No. of Patients (%)
Placebo
Arm, N5 123
Pazopanib
Arm, N5246
Age: Median [range], years 51.9 [18.8-78.6] 56.7 [20.1-83.7]
WHO performance status
0 56 (45.5) 113 (45.9)
1 67 (54.5) 133 (54.1)
Histology, local
Leiomyosarcoma 50 (40.7) 115 (46.7)
Synovial sarcoma 14 (11.4) 30 (12.2)
Other type 59 (48) 101 (41.1)
Grade, locala
Low 3 (2.4) 24 (9.8)
Intermediate 30 (24.4) 63 (25.6)
High 90 (73.2) 159 (64.6)
Prior (neo)adjuvant therapy 36 (29.3) 58 (23.6)
Number of prior lines of therapy
for advanced disease
110 (89.4) 232 (94.3)
0-1 52 (42.3) 110 (44.7)
2-4 71 (57.7) 136 (55.3)
Abbreviations: WHO, World Health Organization.
a Local grade at the time of initial diagnosis is indicated.
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Other Scales
Among the other scales of the EORTC QLQ-C30, there
were both statistically and clinically significant differences
in scores between the 2 treatment arms for diarrhea, loss
of appetite, nausea/vomiting, and fatigue (Table 3).
Patients who reported at least 1 minimally important wor-
sening (ie, an increase10 points) in any of those 4 symp-
tom scales are summarized in Table 4. No significant
differences were observed in scores on any of the function-
ing scales (physical, emotional, role, social and cognitive
functioning), although the results for role functioning
were statistically but not clinically significant. All differen-
ces were in favor of the placebo arm.
Exploratory Post-Hoc Analyses
Exploratory factor analysis revealed that GHS scores were
associated mainly with functioning scales (physical, role,
and social) and less with symptom scales, with the excep-
tion of fatigue. Linear regression of the various EORTC
QLQ-C30 scales on the GHS score revealed that current
GHS was linked with role functioning, social functioning,
fatigue, and pain. Future GHS (ie, the GHS score
reported at the next assessment) was linked with role func-
tioning, social functioning, and fatigue only. Pazopanib
dose intensity before week 4 was significantly related to
the fatigue score at week 4 (P5 .006). However, no corre-
lations with HRQoL parameters were observed at the
week-8 or week-12 time points.
The results of prognostic factor analyses of the
effects of baseline GHS scores and changes in GHS scores
from baseline to the week-4 assessment on PFS and OS
are summarized in Table 5. A statistically significant effect
was observed for the baseline GHS score on OS, in which
patients who had GHS scores 50 had poorer survival
(9.1 months vs 13.7 months; P5 .0002) (Fig. 2).
Systematic Review
We searched the PubMed database using the search
terms “pazopanib,” and “soft tissue sarcoma,” and
TABLE 3. Summary of the Health-Related Quality-of-Life Results
QLQ-C30 Scales
Primary Scale
of Interest Secondary Scales of Interest
Sensitivity
Analysis
GHS Diarrhea Loss of
Appetite
Nausea/Vomiting Fatigue Role
Functioning
Imputed
GHS
P-value for test of overall difference
.291 < .001 < .001 < .001 0.012 0.039 0.272
Difference between treatment arms (95% CI)a
Baseline 1.4 (23.7, 6.4) 1.9 (22.1, 5.8) 0.1 (26.1, 6.3) 20.2 (23.2, 2.8) 21.0 (26.6, 4.7) 1.4 (25.7, 8.5) 1.7 (23.0, 6.3)
Wk 4 23.8 (29.0, 1.3) 19.0 (12.4-25.6) 15.3 (7.9-22.6) 8.3 (3.8-12.8) 10.1 (3.9-16.2) 29.5 (217.1, 21.9) 22.9 (27.6, 1.8)
Wk 8 22.3 (28.3, 3.7) 26.4 (18.3-34.6) 17.1 (7.9-26.3) 11.0 (5.1-16.8) 7.6 (1.0-14.3) 28.1 (216.8, 0.6) 23.2 (28.3, 1.9)
Wk 12 21.6 (28.4, 5.1) 20.9 (10.4-31.5) 13.2 (3.3-23.2) 12.3 (5.8-18.9) 4.5 (23.3, 12.4) 24.9 (214.5, 4.6) 20.7 (26.3, 4.9)
Abbreviations: GHS, general health status; QLQ-C30, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire core 30.
a Estimates for the differences between treatment arms were calculated using linear mixed modelling and are expressed in absolute score points on the scale.
For the GHS and role functioning scales, positive numbers indicate a higher value (better quality of life) for pazopanib compared with placebo. For the symp-
tom scales (diarrhea, loss of appetite loss, nausea/vomiting, and fatigue), positive numbers indicate a higher level of symptoms (worse quality of life) for pazo-
panib compared with placebo.
Figure 1. Mean global health status (GHS) scores and corre-
sponding 95% confidence intervals (CIs) were estimated
using the model. In both treatment arms, the GHS scores
tended to decline over time.
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“quality of life,” and “patient-reported outcome” up
to March 2013, restricting the search to English-
language publications. We then reviewed the abstracts
to exclude articles that did not evaluate HRQoL in
detail. Only 2 relevant articles were identified: the
2012 publication of the phase 3 PALETTE trial by
van der Graaf et al8 and a review article by Deeks21
that mainly reiterates the PALETTE results.
DISCUSSION
HRQoL was an important exploratory endpoint of the
phase 3 PALETTE trial. The results obtained from the
prespecified analysis demonstrated that pazopanib had no
significant impact on GHS. Various sensitivity analyses
(using different populations, methodologies, or out-
comes) supported the primary analysis, indicating that
pazopanib can be administered in this patient population
TABLE 4. Sensitivity Results on General Health Status Summary Statistics
Placebo Arm, N5 123 Pazopanib Arm, N5 246
GHS score
Change from baseline until
last score
Median
Mean (SD)
0.0
25.13 (15.27)
0.0
26.82 (22.43)
Change from baseline to
minimum score
Median
Mean (SD)
28.3
28.61 (16.12)
216.7
214.83 (23.55)
Change from baseline to
average score
Median
Mean (SD)
22.8
25.01 (17.15)
28.3
27.82 (21.99)
10-Points decrease from
baseline
event/evaluablea
%
30/91
33
107/191
56
Clinically relevant deterioration from baseline in any key symptom scale
(diarrhea, loss of appetite , nausea/vomiting or fatigue)
At week 4 event/evaluablea
%
53/90
58.9
162/186
87.1
At week 8 event/evaluablea
%
30/51
58.8
121/142
85.2
At week 12 event/evaluablea
%
16/28
57.1
102/121
84.3
Overall event/evaluablea
%
63/93
67.7
184/195
94.4
Abbreviations: GHS, general health status; SD, standard deviation.
a An event is defined as having experienced at least one score that is at least 10 points higher than the score reported at baseline (ie. indicating a clinical rele-
vant deterioration in that symptom). Patients are evaluable if they have a valid baseline, at least one follow-up assessment and on-treatment at the time-point
of interest.
TABLE 5. Prognostic Value of the Global Health Status Score
Variable
No.
of Patients
No. of
Observed Events HR (95% CI) Wald P
Median
Survival, mo
PFS
Baseline GHS score 0.89 (0.69-1.15) .381
50 132 99 2.7
>50 206 154 2.8
Change in GHS score 0.90 (0.68-1.21) .502
 210 93 71 2.9
> 210 175 134 2.8
OS
Baseline GHS score 50/>50 0.58 (0.44-0.77) < .001
50 132 91 9.1
>50 206 108 13.7
Change in GHS score 0.98 (0.69-1.37) .886
 10 93 51 13.1
> 210 175 98 12.3
Abbreviations: CI, confidence interval, GHS, global health status; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
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without relevant deterioration in perceived overall health
or HRQoL status. The objective of the current study was
to demonstrate whether GHS could be improved by the
administration of pazopanib, which was not the case.
However, achieving a delay in PFS without an impair-
ment in GHS is considered a meaningful result.
Significantly worse outcomes in the pazopanib arm
were observed for 4 symptoms scales: diarrhea, appetite
loss, nausea/vomiting, and fatigue. These results are in
line with the known toxicity profile of pazopanib and
angiogenesis inhibitors in general. The most frequently
cited side effects of pazopanib treatment in patients with
STS include hypertension, skin reactions, gastrointestinal
disturbances, and fatigue.6,8,22 Similar observations are
reported in other cancers, most notably renal cell carci-
noma.23,24 However, a notable point is that, despite their
impact on these 4 symptom scales, the side effects did not
translate into worse GHS or functional scale scores. Only
the role-functioning scale, which measures the ability to
continue daily tasks and work, was borderline worse in the
pazopanib arm. Its maximum observed difference of 9.5
points (95%CI, 17.1-1.9 points), which occurred at week
4, was just short of clinical significance. There also did not
seem to be any strong evidence that HRQoL affected
treatment compliance, with fatigue at the week-4 time
point the only event related to pazopanib dose intensity.
This may be because patients became accustomed to the
pazopanib dosing and side effects early in their treatment
period. However, it should be noted that these results
stem from an exploratory, post-hoc analysis and may not
be reliable.
Currently, there is limited information in the litera-
ture on the HRQoL impact of pazopanib administration
in patients with advanced STS. Even general information
on HRQoL in advanced STS after first-line treatment is
scarce: only 6 randomized trials (this study and 5 phase 2
trials) have been published since 1980.7 HRQoL results
are more common in extremity STS in patients with
early/localized disease.25-27 For this population, surgical
options and impairment in physical functioning are obvi-
ously the dominant issues, as is the lack of patient input in
decisions regarding treatment.27 Reichardt et al2 recently
reported on HRQoL and health state utilities specifically
among patients with metastatic STS and bone sarcoma
(excluding gastrointestinal stromal tumors) who had
attained a favorable response to chemotherapy, whereas
Shingler et al3 reported on STS health state utilities in
general. Their observations are similar to those obtained
in our current study, with the authors reporting fatigue as
a major driver in reduced overall HRQoL. Both groups
reported a general decline in HRQoL over time, most
likely caused by the underlying disease burden. Moreover,
their results highlighted the significant negative impact of
disease progression, because patients who developed pro-
gressive disease consistently reported lower HRQoL.
Beyond STS, there have been other studies examin-
ing the impact of pazopanib on HRQoL. Most notably,
Cella et al28 investigated the HRQoL of patients who
were receiving pazopanib for advanced renal cell carci-
noma. Those authors observed a favorable risk-benefit
profile with pazopanib, leading to a delay in HRQoL
deterioration compared with placebo. This delay in
HRQoL deterioration was related to a delay in PFS;
because, in that study, the development of disease progres-
sion was considered HRQoL deterioration by definition.
Recently, a direct comparison of sunitinib versus
Figure 2. Overall survival is illustrated according to baseline
global health status (GHS) scores in (A) all patients and
(B) per treatment arm, the placebo arm (Pbo) versus the
pazopanib arm (Paz). A statistically significant effect on
overall survival was observed for the baseline score, in which
patients who had GHS scores 50 had poorer survival. N
indicates the number of patients; O, number of observed
events.
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pazopanib in metastatic renal cell carcinoma demon-
strated similar efficacy but safety and quality-of-life pro-
files in favor of pazopanib.29 This was confirmed in a
patient preference study in which patients preferred pazo-
panib over sunitinib, citing quality of life in general and
fatigue in particular as important reasons.30
The prognostic value of the baseline GHS scores for
OS confirm previous reported findings that baseline
HRQoL scores can act as a universal prognostic factor
across many cancer disease sites.31 Patients who had GHS
scores <50 at baseline had lower OS but similar PFS, in-
dependent of the treatment arm. Normative scores for
GHS are typically approximately 65 to 70, depending on
age, sex, and other chronic diseases.32,33 Similar values
were observed at baseline in this trial, but the outcomes
tended to decline slightly to<60 over time.
Our study was not without limitations. A major con-
straint was the lack of HRQoL collection after progression,
especially because the treatment effect on PFS did not
translate into a significant OS benefit. Therefore, the ques-
tion remains: How significant was the overall benefit of
pazopanib in terms of quality-adjusted life-years? In addi-
tion, the PFS benefit in the pazopanib arm caused lower
attrition rates and, thus, a longer HRQoL observation pe-
riod compared with the placebo arm. Combined with a
general decline in HRQoL scores over time, lower scores in
the pazopanib armmay have been influenced by the higher
number of HRQoL observations in the treatment arm.
Missing data constitute a common challenge to
HRQoL assessment in clinical trials.34 Compliance in the
PALETTE trial was good and remained within acceptable
limits to allow the performance of analyses as intended.
Sensitivity analyses confirmed the results, and an investi-
gation into the causes of missing data revealed no system-
atic bias. Although the QLQ-C30 is often cited currently
as 1 of the most commonly used and validated measures
applied within the oncology clinical trials setting, when
applied to this particular study, several side-effect scales/
items or symptoms common to angiogenesis inhibitors
are lacking. Most notably absent are symptoms related to
hand-foot syndrome or skin reactions. These symptoms
represent a severe limitation to the patient when perform-
ing normal daily activities. Similar to hair loss for cyto-
toxic regimens, dermatologic problems may be
considered more important by patients because of their
chronicity, obvious appearance, and social impact, thus
affecting daily activities more than might be apparent
from a clinical perspective.
It should be noted that there is no questionnaire
specific for patients with advanced STS; and, given the
heterogeneity of this disease, the development of such an
instrument may be challenging. The EORTCQuality-of-
Life Group uses a module-based approach to question-
naire development, in which the core questionnaire
(EORTC QLQ-C30) is supplemented with disease-
specific, treatment-specific, or symptom-specific mod-
ules. Currently, no STS-specific module exists, but a
symptom-based module on targeted therapies is under
construction.35 Fatigue-specific instruments, such as the
EORTC QLQ-FA1336 or the Functional Assessment of
Cancer Treatment-Fatigue,37 could be a valuable consid-
eration for future trials with angiogenesis inhibitors.
Conclusion
HRQoL was an important exploratory endpoint in this
comparison between pazopanib and placebo in patients
with advanced STS. The primary selected scale, the
EORTCQLQ-C30 GHS, revealed no statistically or clin-
ically significant differences between the 2 treatment arms
at any time point. Sensitivity analyses confirmed this find-
ing. The toxicity profile of pazopanib was reflected in
patients’ self-reported symptoms (fatigue, nausea/vomit-
ing, appetite loss, and diarrhea) but did not translate into
significantly worse overall global health during treatment.
HRQoL scores tended to decline over time in both arms,
at least in part reflecting the underlying disease burden in
this patient population.
FUNDING SUPPORT
This study was sponsored by GlaxoSmithKline.
CONFLICT OF INTEREST DISCLOSURES
Prof. van der Graaf reports speaker’s fee from GlaxoSmithKline
(GSK) outside the submitted work. Prof. Blay reports research sup-
port and honoraria from GSK, Novartis, PharmaMar, MSD Phar-
maceuticals, and Roche outside the submitted work; Ms Manson
and Rachel Hodge are employed by and hold shares in GSK; Dr.
Lugowska reports personal fees from Roche, Bristol Myers Squibb,
and GSK outside the submitted work; Dr. Sanfilippo reports grants
and personal fees from GSK outside the submitted work.
Dr. Judson reports personal fees from GSK, during the conduct of
the study; personal fees from Bayer, Ariad, and Merck-Serono,
outside the submitted work. Dr. Chawla has been a consultant for
Amgen, Roche, Cytrx, Threshold, GSK and Berg Pharma outside
the submitted work.
REFERENCES
1. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in
adults. N Engl J Med. 2005;353:701-711.
2. Reichardt P, Leahy M, Garcia Del Muro X, et al. Quality of life
and utility in patients with metastatic soft tissue and bone sarcoma:
the Sarcoma Treatment and Burden of Illness in North America and
Europe (SABINE) Study [serial online]. Sarcoma 2012:740279,
2012.
Original Article
2940 Cancer September 1, 2015
3. Shingler SL, Swinburn P, Lloyd A, et al. Elicitation of health state
utilities in soft tissue sarcoma. Qual Life Res. 2013;22:1697-1706.
4. Demetri GD, von MM, Blanke CD, et al. Efficacy and safety of
imatinib mesylate in advanced gastrointestinal stromal tumors. N
Engl J Med. 2002;347:472-480.
5. Scurr M. Histology-driven chemotherapy in soft tissue sarcomas.
Curr Treat Options Oncol. 2011;12:32-45.
6. Sleijfer S, van der Graaf WT, Blay JY. Angiogenesis inhibition in
non-GIST soft tissue sarcomas. Oncologist. 2008;13:1193-1200.
7. Sharma S, Takyar S, Manson SC, Powell S, Penel N. Efficacy and
safety of pharmacological interventions in second- or later-line treat-
ment of patients with advanced soft tissue sarcoma: a systematic
review [serial online]. BMC Cancer. 2013;13:385.
8. van der Graaf WT, Blay JY, Chawala SP, et al. EORTC Soft Tissue
and Bone Sarcoma Group; PALETTE Study Group. Pazopanib for
metastatic soft-tissue sarcoma (PALETTE): a randomized, double-
blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879-1886.
9. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Orga-
nization for Research and Treatment of Cancer QLQ-C30: a
quality-of-life instrument for use in international clinical trials in on-
cology. J Natl Cancer Inst. 1993;85:365-376.
10. EuroQol Group. EuroQol—a new facility for the measurement of
health-related quality of life. Health Policy. 1990;16:199-208.
11. Calvert M, Blazeby J, Altman DG, et al. Reporting of patient-
reported outcomes in randomized trials: the CONSORT PRO
extension. JAMA. 2013;309:814-822.
12. Amdahl J, Manson SC, Isbell R, et al. Cost-effectiveness of pazopa-
nib in advanced soft tissue sarcoma in the United Kingdom [serial
online]. Sarcoma 2014:481071, 2014.
13. Delea TE, Amdahl J, Nakhaipour HR, et al. Cost-effectiveness of
pazopanib in advanced soft-tissue sarcoma in Canada. Curr Oncol.
2014;21:748-759.
14. De Wolf, L, Koller M, Velikova G, Johnson C, Scott N, Bottomley
A. EORTC Translating Procedures. Brussels, Belgium: EORTC
Quality of Life Study Group Publications; 2009.
15. Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D,
Bottomley A. EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels,
Belgium: EORTC Publications; 2001.
16. Young T, de Haes H, Fayers P, et al. Guidelines for Assessing Qual-
ity of Life in Clinical Trials. Brussels, Belgium: EORTC Quality of
Life Study Group Publications; 1999.
17. Akaike H. Information measures and model selection. Bull Int Stat
Inst. 1983;44:277-291.
18. Fairclough D. Design and Analysis of Quality of Life Studies in
Clinical Trials. New York: Chapman & Hall; 2002.
19. Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance
of changes in health-related quality-of-life scores. J Clin Oncol. 1998;
16:139-144.
20. Efficace F, Osoba D, Gotay C, Sprangers M, Coens C, Bottomley
A. Has the quality of health-related quality of life reporting in cancer
clinical trials improved over time? Towards bridging the gap with
clinical decision making. Ann Oncol. 2007;18:775-781.
21. Deeks ED. Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012;
72:2129-2140.
22. Sch€offski P. Pazopanib in the treatment of soft tissue sarcoma.
Expert Rev Anticancer Ther. 2012;12:711-723.
23. Sleijfer S, Ray-Coquard I, Papai Z, et al. Antiangiogenic therapy for
advanced renal cell carcinoma: management of treatment-related tox-
icities. J Clin Oncol. 2009;27:3126-3132.
24. Cohen RB, Oudard S. Antiangiogenic therapy for advanced renal
cell carcinoma: management of treatment-related toxicities. Invest
New Drugs. 2012;30:2066-2079.
25. Peiper M, Matthaei H, B€olke E, et al. Compartmental resection for
subfascial extremity soft tissue sarcoma and quality of life in long-
term survivors. Wien Klin Wochenschr. 2011;123:488-495.
26. Schreiber D, Bell RS, Wunder JS, et al. Evaluating function and
health related quality of life in patients treated for extremity soft tis-
sue sarcoma. Qual Life Res. 2006;15:1439-1446.
27. Thijssens KM, Hoekstra-Weebers JE, van Ginkel RJ, Hoekstra HJ.
Quality of life after hyperthermic isolated limb perfusion for locally
advanced extremity soft tissue sarcoma. Ann Surg Oncol. 2006;13:
864-871.
28. Cella D, Pickard AS, Duh MS, et al. Health-related quality of life
in patients with advanced renal cell carcinoma receiving pazopanib
or placebo in a randomised phase III trial. Eur J Cancer. 2012;48:
311-323.
29. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib
in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722-
731.
30. Escudier BJ, Porta C, Bono P, et al. Patient preference between
pazopanib (Paz) and sunitinib (Sun): results of a randomized
double-blind, placebo-controlled, cross-over study in patients with
metastatic renal cell carcinoma (mRCC) PISCES study, NCT
01064310 [abstract]. J Clin Oncol. 2012;30(18 suppl). Abstract
CRA4502.
31. Quinten C, Coens C, Mauer M, et al. EORTC Clinical Groups.
Baseline quality of life as a prognostic indicator of survival: a meta-
analysis of individual patient data from EORTC clinical trials. Lan-
cet Oncol. 2009;10:865-871.
32. Waldmann A, Schubert D, Katalinic A. Normative data of the
EORTC QLQ-C30 for the German population: a population-based
survey [serial online]. PLoS One. 2013;8:e74149.
33. Klee M, Groenvold M, Machin D. Quality of life of Danish
women: population-based norms of the EORTC QLQ-C30. Qual
Life Res. 1997;6:27-34.
34. Bottomley A, Aaronson NK; European Organisation for Research
and Treatment of Cancer. International perspective on health-related
quality-of-life research in cancer clinical trials: the European Organi-
sation for Research and Treatment of Cancer experience. J Clin
Oncol. 2007;25:5082-5086.
35. Sodergren SC, White A, Efficace F, et al. Systematic review of the
side effects associated with tyrosine kinase inhibitors used in the
treatment of gastrointestinal stromal tumours on behalf of the
EORTC Quality of Life Group. Crit Rev Oncol Hematol. 2014;91:
35-46.
36. Weis J, Arraras JI, Conroy T, et al. Development of an EORTC
quality of life phase III module measuring cancer-related fatigue
(EORTC QLQ-FA13) [published online ahead of print May 4,
2012]. Psychooncology. doi: 10.1002/pon.3092.
37. Yellen S, Cella D, Webster K, Blendowski C, Kaplan E. Measuring
fatigue and other anemia-related symptoms in the Functional Assess-
ment of Cancer Therapy (FACT) measurement system. J Pain Symp-
tom Manage. 1997;13:63-74.
HRQoL of Pazopanib in Pretreated STS/Coens et al
Cancer September 1, 2015 2941
